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Abstract
A genetic origin is estimated in 30% of infertile men with the common phenotypes of oligo- or azoospermia, but the
pathogenesis of spermatogenic failure remains frequently obscure. To determine the involvement of Copy Number Variants
(CNVs) in the origin of male infertility, patients with idiopathic severe oligozoospermia (N=89), Sertoli-cell-only syndrome
(SCOS, N=37)) and controls with normozoospermia (N=100) were analysed by array-CGH using the 244A/400K array sets
(Agilent Technologies). The mean number of CNVs and the amount of DNA gain/loss were comparable between all groups.
Ten recurring CNVs were only found in patients with severe oligozoospermia, three only in SCOS and one CNV in both
groups with spermatogenic failure but not in normozoospermic men. Sex-chromosomal, mostly private CNVs were
significantly overrepresented in patients with SCOS. CNVs found several times in all groups were analysed in a case-control
design and four additional candidate genes and two regions without known genes were associated with SCOS (P,1610
23).
In conclusion, by applying array-CGH to study male infertility for the first time, we provide a number of candidate genes
possibly causing or being risk factors for the men’s spermatogenic failure. The recurring, patient-specific and private, sex-
chromosomal CNVs as well as those associated with SCOS are candidates for further, larger case-control and re-sequencing
studies.
Citation: Tu ¨ttelmann F, Simoni M, Kliesch S, Ledig S, Dworniczak B, et al. (2011) Copy Number Variants in Patients with Severe Oligozoospermia and Sertoli-Cell-
Only Syndrome. PLoS ONE 6(4): e19426. doi:10.1371/journal.pone.0019426
Editor: Laszlo Orban, Temasek Life Sciences Laboratory, Singapore
Received November 23, 2010; Accepted April 3, 2011; Published April 29, 2011
Copyright:  2011 Tu ¨ttelmann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Deutsche Forschungsgemeinschaft Research Unit ‘Germ Cell Potential’ (FOR 1041, grant TU 298/1-1). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: frank.tuettelmann@ukmuenster.de
Introduction
Infertility, which affects 10–15% of all couples, is attributed to a
male (co-)factor in around 50%. Male infertility is mostly caused
by spermatogenic failure, clinically noted as oligo- or azoospermia.
However, the reasons for the decreased sperm production remain
largely unclear: After a full clinical workup around 30% of cases
are considered ‘idiopathic infertile’ and an additional 40% have
not sufficient/uncertain causes (e.g. varicocele, infections) [1,2].
On the other hand, it is estimated that about 30% of azoo-/
oligozoospermia are caused by chromosomal abnormalities or
mutations of genes involved in germ cell production and function
[3]. Thus, male infertility of genetic origin supposedly affects about
1 in 40 adult men and can be considered a common, complex
disease.
The currently established genetic causes of male infertility
comprise abnormalities on all genomic levels from chromosomal
abnormalities, in particular Klinefelter syndrome, to Y-chromo-
somal (azoospermia factor, AZF) deletions, to mutations of the
cystic fibrosis transmembrane conductance regulator (CFTR, all
gene information - name, location, IDs - available as Table S1)
gene. However, although routinely performed in clinical workup
[4] karyotyping, AZF deletion screening and CFTR sequencing
elucidate the reason for infertility in only 5% of unselected and
around 20% of azoospermic patients [1,2].
A multitude of up to 1,500 genes are thought to be involved in
spermatogenesis of which 300–600 are specifically expressed in the
male germline [5–7] and are therefore candidates for causing male
infertility. In the last 5–10 years, many efforts have been
undertaken with research focused on targeted re-sequencing of a
number of these candidate genes. Nevertheless, up to date no
additional genetic cause is recognised to be administrable in
patient care, mostly because results have either not been replicated
or might only explain minute effects [8–10].
Copy Number Variants (CNVs) have been shown to be an
important source of genetic diversity with remarkable differences
between individuals and to play a role in complex diseases such as
mental retardation, schizophrenia and cancer [11,12]. Recently,
CNVs have also been analysed in premature ovarian failure
(POF), XY gonadal dysgenesis and Mayer-Rokitansky-Ku ¨ster-
Hauser syndrome, diseases linked to genital development and
function [13–15]. To date, CNVs have not been analysed in men
with spermatogenic failure and we hypothesised that CNVs cause
spermatogenic failure by either of the following mechanisms: An
increased number or specific distribution of CNVs could result in
defective recombination, meiotic failure and loss of germ cells.
CNVs might also affect the activity of individual genes important
for spermatogenesis. We therefore performed high-resolution
array Comparative Genomic Hybridisation (array-CGH) in
groups of well-characterised idiopathic infertile men with oligo-
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were analysed, because the current databases of structural
genomic variation do not provide the necessary information when
evaluating spermatogenesis and fertility. We wanted to determine
a) whether the number and/or pattern in selected men with
spermatogenic failure differs from that in men with normal
spermatogenesis; b) whether recurrent CNVs can be identified
which might harbour genes involved in spermatogenesis; c)
associations with reproductive parameters.
Materials and Methods
Study population
Caucasian patients of German origin with idiopathic infertility
were selected from the clientele of the Department of Clinical
Andrology of the Centre of Reproductive Medicine and
Andrology, Mu ¨nster, a tertiary-referral centre, using the Andro-
base database [16]. All participants underwent a complete
physical examination including ultrasonographic analysis of the
Table 1. Comparison of clinical parameters between the study groups (mean 6 standard deviation and median, range (min-max)
in brackets).
Normozoospermic controls (N=100) Severe oligozoospermia (N=89) Sertoli-cell-only syndrome (N=37)
Age [y] 40.164.4 (40, 30–59) 38.765.8 (39, 23–58) 40.365.4 (40, 29–50)
Testicular volume [ml] 58618 (59, 22–111) 41613 (39, 12–89)
** 29611 (30, 10–56)
**
LH [U/l] 3.161.2 (3.0, 0.7–7.1) 4.562.3
** (4.0, 1.5–14.1) 7.863.2
** (6.7, 3.1–15.6)
FSH [U/l] 3.762.0 (3.1, 1.3–9.4) 7.765.4
** (5.7, 1.2–24.5) 15.364.9
** (21.1, 8.5–37.9)
Testosterone [nmol/l] 16.465.1 (15.9, 6.9–39.0) 15.364.9 (15.0, 4.6–31.3) 14.165.8 (12.4, 7.6–34.4)
**
Abstinence [d] 3.961.6 (4, 2–7) 3.861.3 (4, 2–7) 4.261.2 (4, 2–10)
Sperm concentration [10
6/ml] 77.0647.0 (62.0, 20.0–231.0) 1.461.2
** (1.1, 0.1–5.0) 0
**
Semen volume [ml] 3.961.5 (3.5, 2.0–9.0) 3.661.4 (3.4, 1.5–9.2) 4.161.8 (4.0, 1.0–10.0)
Total sperm count [10
6] 287.36182.1 (269.5, 40.0–1083.5) 4.563.3
** (3.8, 0.3–10.0) 0
**
a+b Motility [%] 53.765.9 (54, 36–75) 32.4613.0
** (31, 4–60) -
Normal morphology [%] 16.765.2 (16, 10–34) 6.065.6
** (5, 1–24) -
**significantly different compared to controls (P,0.01 calculated by Mann-Whitney test).
doi:10.1371/journal.pone.0019426.t001
Figure 1. Workflow with different arrays (244A, 400K), number of subjects and categorisation of CNVs.
doi:10.1371/journal.pone.0019426.g001
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7 days of sexual abstinence and all semen values were determined
in accordance with the then current WHO criteria [17]. All men
with known clinical (e.g. maldescended testes, varicocele, infec-
tions) and genetic (karyotype anomalies, Y-chromosomal deletions)
causes of infertility were excluded. Of these men, one-hundred
with $20610/ml sperm concentration, $40610
6 total sperm
count, $2 ml semen volume, $50% of a+bo r$25% a motility,
high percentage of normal forms ($10%) were selected as control
population with normal spermatogenesis according to WHO
criteria [17]. Twenty-one (21%) of these men had previously
induced a spontaneous pregnancy in the current or a former
relationship. The study populations comprised patients with a)
severe oligozoospermia (N=89 with #5610
6/ml sperm concen-
tration and #10610
6 total sperm count) and b) azoospermia and
complete bilateral Sertoli-cell-only syndrome (SCOS, N=37). The
diagnosis of SCOS was established if only tubules with Sertoli-cells
were detected in bilateral and multilocular (at least two sites per
testis) testicular biopsies and the attempt of testicular sperm
extraction (TESE) was unsuccessful.
Ethics statement
All participants gave written informed consent for evaluation of
their clinical data and genetic analysis of their donated DNA
samples according to a protocol approved by the Ethics
Committee of the Medical Faculty in Mu ¨nster and State Medical
Board.
Array-CGH
Genomic DNA was extracted from peripheral blood by
standard methods and analysed at first by the commercially
available Human Genome CGH Microarray Kits 244A (Agilent
Technologies, Santa Clara, California, USA). This array com-
prises 236,381 60-mer oligonucleotide probes with a median probe
spacing of 8.9 Kb. During the course of the study, the higher-
resolution 400K microarray with 411,056 oligonucleotides and a
median probe spacing of 5.3 Kb became available. We switched to
using this array to be able to compare the impact of smaller CNVs
detected with the higher-resolution on spermatogenic failure.
Finally, 78 control men and 42 with severe oligozoospermia were
analysed with the 244A arrays and 22 and 47 with the 400K
arrays. All azoospermic patients with SCOS were analysed with
the 400K arrays. Each patient’s DNA was compared to 10 pooled
DNAs (Promega Human Genomic DNA: Male, Cat.-Nr. G1471).
Labelling and hybridisation were performed according to the
manufacturer’s protocol. In brief, 1 mg of patients’ DNA and the
pooled control DNA were double-digested with AluI and RsaI
(Promega, Madison, Wisconsin, USA) and subsequently labelled
with Cy5- and Cy3-dUTP using the Genomic DNA Enzymatic
Labeling kit (Agilent Technologies), respectively. After purification
of the labelled DNA by filtration (Microcon YM-30, Millipore,
Bilerica, Massachusetts, USA), patient and control DNA were
pooled and hybridised with 25 mg of human COT DNA
(ArrayGrade KREACot DNA, Kreatech, Amsterdam, The
Netherlands) for 40 h at 65uC in the hybridisation oven (Agilent
Technologies). After post-hybridisation washes, the arrays were
scanned using a Microarray Scanner (G2565BA, Agilent Tech-
nologies), and the spot intensities were measured by ‘Feature
Extraction Software’ (version 10.7, Agilent Technologies). Anal-
yses and visualisation were performed with ‘DNA Analytics’
(version 4.0.81, Agilent Technologies) with the following param-
eters: aberration algorithm ADM-2, threshold 6.0, fuzzy zero,
centralisation and moving average window 1 Mb. Aberrant signals
including 4 or more adjacent probes were considered as genomic
CNVs. The raw array-data acquired by the Feature Extraction
Software is accessible through the Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo, series record
GSE27965) and the abstracted CNVs were submitted to the
Database of genomic structural variation (dbVar, http://www.
ncbi.nlm.nih.gov/dbvar, study ID nstd53). CNVs found in
normozoospermic controls are also available as Table S2. The
Database of Genomic Variants (DGV, http://projects.tcag.ca/
variation/) was used to compare findings to previously reported
studies. Coordinates of CNVs are based on the National Center
for Biotechnology Information (NCBI) Human Genome Build 36
(hg18).
Statistical analysis
Comparisons between patients and controls were carried out
using the two-sample t-tests if data were normally distributed
(e.g. number of CNVs) and otherwise non-parametric Mann-
Whitney test. Frequencies were compared by Fisher’s exact test.
In principle, P-values less than 0.05 were considered statistically
significant. To correct for multiple testing, P-values were
adjusted according to the Bonferroni-Holm procedure, which
is less conservative than the standard Bonferroni correction. As
semen parameters were not normally distributed, correlations
were calculated for log-transformed values. All calculations
were performed with Stata/SE (StataCorp LP, version 9.1,
College Station, Texas, USA) or GraphPad Prism version 5.00
for Windows (GraphPad Software, San Diego, California,
USA).
Table 2. Detected CNVs and amount of DNA change per man separately for each array resolution (mean 6 standard deviation).
Normozoospermic controls Severe oligozoospermia
Sertoli-cell-only
syndrome
Array 244A 400K 244A 400K 400K
CNVs [N] 10.963.0 20.665.7 10.262.8 18.566.3 19.765.9
Duplications [N] 5.062.5 11.365.0 4.962.4 8.863.8 9.264.1
Deletions [N] 5.962.3 9.463.0 5.462.1 9.663.8 10.563.4
DNA change [Kb] 273261335 30766842 301561383 331362257 308761292
DNA gain [Kb] 151061234 164961144 184261414 176161219 14646850
DNA loss [Kb] 12236745 14276730 11736932 155161841 16246950
No significant differences were found between the study groups. P-values calculated by two-sample t-tests.
doi:10.1371/journal.pone.0019426.t002
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Clinical data
The clinical parameters of the normozoospermic controls and
the two study groups with severe oligozoospermia and azoosper-
mia caused by SCOS are presented in Table 1. Testicular volume
was lower and LH as well as FSH higher in the two groups with
spermatogenic failure. Patients with SCOS also had lower
testosterone serum levels. Duration of abstinence and semen
volume were comparable between all groups. Sperm concentra-
tion and count as well as percentage of sperm with normal
morphology and progressive motility were significantly different by
selection.
Comparison of CNVs between groups
In total, 1304 CNVs were detected in 100 controls, 1297 CNVs
in oligozoospermic men (N=89) and 728 CNVs in patients with
SCOS (N=37); the numbers and categorisations of CNVs are
depicted in Figure 1. CNV size ranged from 1.9 Kb to 4.7 Mb
with only 5% larger than 1 Mb. The number of detected CNVs
and amount of DNA change per men is presented in Table 2
according to study group. As expected from the two-fold increased
resolution, around twice as many CNVs and also duplications/
deletions separately were found with the higher-resolution 400K
array (Fig. 2). The amount of DNA change did not increase
likewise with the 400K arrays, as mostly smaller CNVs were
additionally detected. Overall, no significant differences in number
of CNVs (Fig. 2) or amount of DNA change were found between
controls and the two study groups. In addition, particularly large
(.500 Kb, .1 Mb) CNVs were analysed, but did not show
different distributions between groups.
To analyse whether the chromosomal distribution of CNVs was
different between the groups, the number of CNVs, and
duplications/deletions separately, was calculated per chromosome
and normalised to 100 men (Fig. 3). The overall distribution of
duplications and deletions was found to be significantly different
between all groups (P,0.01) and for both types of arrays. The post-
hoc comparison of number of CNVs per single chromosome
indicated significant differences between patients and controls for
several chromosomes after Bonferroni-Holm correction. The
detailed per-chromosome analysis revealed no specific hotspots
associated with oligozoospermia or SCOS on the respective
chromosomes. In contrast, the differences in the distribution were
caused by recurring CNVs that were found more or less frequently
in the respective study groups (see below).
In many cases, several differently sized CNVs spanned a
common region but probably have different breakpoints. If either
the gene content was identical or the CNVs spanned regions with
the breakpoints distance 610 Kb (roughly corresponding to one
oligonucleotide and thereby the minimum array resolution), these
CNVs were aggregated for statistical analyses. Duplications and
deletions were considered as different variants because of their
supposedly diverse impact. Of the 3329 CNVs, a majority of 2711
(81%) could thereby be summarised as 310 recurring variants (159
deletions and 151 duplications), of which the smallest common
region is then reported. Some of these were only found in
normozoospermic controls (N=21), at most once per group
(N=58) or not in controls (N=14, recurring, patient-specific
CNVs).
The frequencies of the remaining 217 variants were compared
between the study groups (Table S3 and Table S4). Plots of the
2log(10)P-values (Manhattan-plots) of case-control comparisons
are presented in Fig. 4. To correct for multiple testing, the P-value
for selection of candidate CNVs was set to 0.001 and these 6 are
reported in Table 3. Except the decreasing frequency of a deletion
on 4q13.1 including UGT2B17 and a small duplication on
14q32.33 without known genes, all differences remained signifi-
cant also after Bonferroni-Holm correction. Ten recurring CNVs
were only found in patients with severe oligozoospermia, while
three were SCOS specific and one CNV (3p11.1 in an intron of
EPHA3) was found in both groups with spermatogenic failure but
not in normozoospermic men (Table 4). Already from the
chromosomal distribution it became clear, that sex-chromosomal
CNVs were significantly overrepresented in patients with SCOS.
These are all private variants summarised in Table 5. Both groups
of patient-specific CNVs (Table 4 and 5) were marked as ‘likely
pathogenic’ in dbVar. All genes in either CNVs with significantly
different frequencies between patients and controls, patient-
Figure 2. Number of CNVs (A), duplications (B) and deletions
(C) separated by array (left: 244A, right: 400K) and patient
group (Normo=normozoospermia, Oligo=severe oligozoos-
permia, SCOS=Sertoli-cell-only syndrome). Around twice as
many CNVs (independent of type and fitting the roughly two-fold
increased resolution) were detected with the 440K array and in general
more duplications than deletions. No significant differences between
patient groups were found.
doi:10.1371/journal.pone.0019426.g002
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and 5) were checked through PUBMED (http://www.ncbi.nlm.
nih.gov/pubmed) and OMIM (http://www.ncbi.nlm.nih.gov/
omim) searches. Those genes with known expression in the testis
and/or function related to spermatogenesis are presented in
Table 6.
Association of CNVs with semen parameters
Under the hypothesis that accumulating CNVs might lead to
reduced sperm output, the number of total CNVs, duplications
and deletions as well as amount of DNA change was correlated
with sperm concentration and count. Because the number of
deletions varies strongly with the array used, these were analysed
separately. In the largest group, 78 normozoospermic men
analysed by 244A arrays, a significant negative association
(r=20.27, P=0.017, Fig. 5) of number of deletions and total
sperm count was found. Sperm concentration also showed a trend
to be associated with number of deletions (r=20.22, P=0.055).
These correlations were strengthened by corrections for age and
abstinence time (P=0.007 and P=0.051) but could not be
confirmed in the other, however smaller, groups of men analysed
by 400K and/or oligozoospermia. Neither correlations with sperm
motility nor morphology were found in any group.
Discussion
For the first time, we analysed 89 strictly selected patients with
severe oligozoospermia, 37 with azoospermia due to SCOS and
100 with normal spermatogenesis as controls by array-CGH.
Although interpretation of the results would have been more
straightforward if only one type of microarray had been used and
while knowing that amount of DNA available as well as funding
would not permit us to repeat the analyses on the first set of
samples, we favoured switching to the higher resolution array to
detect smaller CNVs in almost half of our subjects, which in the
eand appeared to be beneficial. As result, we report several genes
and genomic regions on autosomes and more pronouncedly on the
sex-chromosomes that might either be risk factors (also found in
Figure 3. Number of duplications (upwards) and deletions (downwards) per chromosome (normalised per 100 men) detected by
244A (A) and 400K (B) arrays for normozoospermic controls, oligozoospermic and SCOS patients (open, grey and black bars,
respectively). Significantly different frequencies between the groups are marked with an asterisk. P-values calculated by Fisher’s exact test. To
correct for multiple testing, P-level for significance was adjusted according to the Bonferroni-Holm procedure.
doi:10.1371/journal.pone.0019426.g003
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spermatogenic failure.
We hypothesised that an increased number or specific
distribution of CNVs could result in defective recombination,
meiotic and thereby spermatogenic failure. Structural chromo-
somal aberrations are found more frequently in men with oligo-
and azoospermia with an emphasis on autosomal translocations in
the former (3–4% compared to 0.5–1.5% in controls) and sex-
chromosomal aneuploidy in the latter (13–16% compared to 0.5–
1%) [18–20]. The causal relation between chromosomal rear-
rangements and impaired sperm production has been suggested to
be a structural effect related to alterations in the process of
chromosome synapsis during meiosis [21], but whether submicro-
scopic chromosomal rearrangements (CNVs) can result in meiotic
recombination defects is not known. By comparing the number of
all CNVs, duplications and deletions separately and amount of
DNA change, gain and loss no significant differences were found
between the groups analysed. The differences in chromosomal
distribution of CNVs were attributed to single, recurring CNVs
(see below). Also particularly large (.1 Mb) variants were not
found more frequently in oligozoospermia or SCOS. Therefore,
only even larger variants of several megabases, microscopically
detectable upon conventional karyotyping, might impair chromo-
some synapsis and meiosis. Whether a size threshold for
chromosomal aberrations having such a ‘‘direct’’, gene-indepen-
dent impact on spermatogenesis exists cannot be concluded from
the presented data. It seems, however, that structural variation
below the detection limit of routine karyotyping should not be
regarded, per se, as an obligate cause of spermatogenic failure.
Considering that translocation carriers may have normal sper-
matogenesis [18–20], the link between (large) structural chromo-
somal variation and spermatogenesis remains to be elucidated.
In principle, CNVs may result in altered gene transcription/
protein function through different mechanisms: they might
encompass dosage-sensitive genes, a deletion may demask a
recessive mutation on the homologous chromosome, genes
overlapped by structural variation may be disrupted directly or a
CNV can exert position effects [22]. By comparing CNVs between
Figure 4. Plots of 2log P-values of frequency comparisons for all recurring CNVs found in patients and controls grouped by
chromosome. P-values calculated by Fisher’s exact test. The figure does not include the Y chromosome because no recurring variants were found
on it.
doi:10.1371/journal.pone.0019426.g004
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*;
percentage in brackets) between patients with oligozoospermia or SCOS and normozoospermia or between SCOS and both other
groups combined.
Region Start End Size [Kb]
Gene
symbol(s) Type Normozoosp.
Sev.
oligozoosp. P
Sertoli-cell-
only
syndrome P
P SCOS vs.
others DGV
4q13.2 69069451 69166014 96.6 UGT2B17 dup 10/100 (10%) 12/89 (13.5%) 0.50132 18/37 (48.6%) 0.00000 0.00000 yes
4q13.2 69069451 69166014 96.6 UGT2B17 del 28/100 (28%) 21/89 (23.6%) 0.51072 1/37 (2.7%) 0.00072 0.00086 yes
7q34 141413152 141438704 25.6 MGAM dup 1/22 (4.5%) 0/47 (0%) 0.31884 10/37 (27%) 0.04059 0.00009 yes
7q34 141413152 141438704 25.6 MGAM del 3/22 (13.6%) 8/47 (17%) 1.00000 4/37 (10.8%) 1.00000 0.56819 yes
12p13.31 9528390 9610254 81.9 dup 1/100 (1%) 9/89 (10.1%) 0.00683 0/37 (0%) 1.00000 0.37395 yes
12p13.31 9528390 9610254 81.9 del 4/100 (4%) 11/89 (12.4%) 0.05618 13/37 (35.1%) 0.00001 0.00005 yes
14q11.2 19268576 19490830 222.3 OR4Q3,
OR4M1,
OR4N2, OR4K2,
OR4K5, OR4K1
dup 10/100 (10%) 13/89 (14.6%) 0.37765 8/37 (21.6%) 0.08990 0.18733 yes
14q11.2 19268576 19490830 222.3 OR4Q3,
OR4M1,
OR4N2, OR4K2,
OR4K5, OR4K1
del 36/100 (36%) 24/89 (27%) 0.21172 2/37 (5.4%) 0.00020 0.00049 yes
14q32.33 105602402 105630289 27.9 dup 8/100 (8%) 5/89 (5.6%) 0.57633 11/37 (29.7%) 0.00370 0.00029 yes
14q32.33 105602402 105630289 27.9 del 14/100 (14%) 12/89 (13.5%) 1.00000 7/37 (18.9%) 0.59345 0.44578 yes
17q21.31 41521344 41566740 45.4 KIAA1267 dup 10/100 (10%) 11/89 (12.4%) 0.64844 1/37 (2.7%) 0.28787 0.13883 yes
17q21.31 41521344 41566740 45.4 KIAA1267 del 6/100 (6%) 9/89 (10.1%) 0.41980 16/37 (43.2%) 0.00000 0.00000 yes
For comparison, the corresponding duplication/deletion (if present in any group) is included independent of P-value. CNVs were checked for occurrence in the
Database of Genomic Variants (DGV).
*If CNVs were only found by higher-resolution 400K-array, the number of all cases is reduced to 22 for normozoospermic controls and to 47 for patients with severe
oligozoospermia (see methods).
SCOS=Sertoli-cell-only syndrome. P-values calculated by Fisher’s exact test. To correct for multiple testing, P-level for significance was adjusted according to the
Bonferroni-Holm procedure. Gene information - name, location, IDs - available as Suppl. Table S1.
doi:10.1371/journal.pone.0019426.t003
Table 4. The 11 and 4 recurring, patient-specific CNVs not found in normozoospermic controls with number of cases, type
(dup=duplication, del=deletion), gene content and whether the CNV was described in the Database of Genomic Variants (DGV).
Group Region Start End Size (Kb) Number, type Gene symbol(s) DGV
Oligozoospermia 2p11.2 89635198 89902565 267.0 2xdel - yes
3p11.1 89476719 89499633 22.0 4xdel EPHA3 yes
4p16.1 8235974 8261720 25.7 2xdup SH3TC1 yes
6p21.31 35143115 35184210 41.1 2xdup ANKS1A no
10q23.1 84138134 84171245 33.1 2xdel NRG3 no
10q23.33 96497202 96536412 39.2 2xdel CYP2C19 no
12q13.3 55866674 55896055 29.4 2xdup LRP1, MIR1228 no
16q22.1 66942648 66967713 25.1 2xdup PRMT7, SMPD3 no
17q12 30624580 30787596 163.0 2xdel SLFN11, SLFN12,
SLFN13
no
18q23 75746093 75779459 33.0 1xdup, 2xdel KCNG2, PQLC1 no
Xq26.3 134120502 134157976 37.5 2xdup CXorf48 yes
SCOS 3p11.1 89476719 89499633 22.9 3xdel EPHA3 yes
8q24.3 145061948 145093349 31.4 1xdup, 1xdel PLEC, MIR661 yes
12p11.21 31132516 31223665 91.1 2xdel DDX11, OVOS2 yes
12q23.1 98491661 98519308 27.6 2xdel ANKS1B no
SCOS=Sertoli-cell-only syndrome. Gene information - name, location, IDs - available as Table S1.
doi:10.1371/journal.pone.0019426.t004
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for severe oligozoospermia and SCOS, respectively, were
identified in more than one patient each (Table 4). In addition,
12 and 14 private, sex-chromosomal CNVs were listed (Table 5)
because these may have a functional consequence of the naturally
haploid genes contained therein. Also private, autosomal CNVs
currently found in one patient each may contribute to the
infertility phenotype, but their significance may only be evaluated
by much larger studies. According to our moderately conservative
approach, six CNVs were found in highly significantly different
frequencies in patients with SCOS but also in controls and may be
new risk factors associated with male infertility. All of these CNVs
remained significant also after Bonferroni-correction. Interesting-
ly, only one CNV in 12p13.31 without known genes was
associated with severe oligozoospermia. The 81.9 Kb deletion
was found with increasing frequency from controls (4%) to
oligozoospermic men (12%) to men with SCOS (35%) as the most
severe phenotype. However, the common deletion polymorphism
in UGT2B17 was found in decreasing frequency while a
duplication of the same locus was found in increasing frequency.
These glucoronidase variants determine urinary excretion of
testosterone [23,24], but have not been studied in male infertility.
Genes may be prioritised according to a known function or
indirectly through their expression in the testis. Therefore, the 4
autosomal and 8 X-chromosomal genes presented in Table 6 are
the distilled outcome of the current study with respect to
identification of new, promising candidate genes. Most of these
were shown to be expressed in Sertoli or germ cells, but their
functions are mostly unknown. EPHA3, ANKS1A and ANKS1B
were mentioned because the Anks proteins were found to
modulate degradation of EphA receptors in mice [25] and
therefore the three genes might represent members of a functional
unity. CNVs altering one of these genes were found in 6 men (7%)
with severe oligozoospermia and 5 (14%) with SCOS.
In two recent studies, our group analysed patients with POF and
XY gonadal dysgenesis by array-CGH [13,14]. Interestingly, the
Table 5. The 12 and 14 private, sex-chromosomal, patient-specific CNVs not found in normozoospermic controls with type
(dup=duplication, del=deletion), gene content and whether the CNV was described in the Database of Genomic Variants (DGV).
Group Region Start End Size (Kb) Type Gene symbol(s) DGV
Oligozoospermia Xp21.3 28162190 28214748 52.0 dup - yes
Xp11.4 38376283 38513841 137.6 dup TSPAN7 no
Xp11.22 52657689 52978139 320.5 dup SSX7, SSX2, SPANXN5,
XAGE5, XAGE3, FAM156A,
FAM156B
yes
Xp11.22 52842080 52909890 67.8 dup SPANXN5, XAGE5, XAGE3 no
Xq22.1 102134796 102496321 361.5 dup BEX1, NXF3, BEX4,
TCEAL8, TCEAL5, BEX2,
TCEAL7
no
Xq22.2 103066101 103190187 124.0 dup TMSB15B, H2BFXP,
H2BFWT, H2BFM
yes
Xq22.3 105010614 105561054 550.4 dup NRK, SERPINA7, MUM1L1 yes
Xq22.3 110238448 110260226 21.0 dup PAK3 no
Xq23 111598447 111621531 23.0 del - no
Xq25 123911267 124039708 128.4 del ODZ1 no
Xq27.1 139706586 139904507 197.9 dup MIR320D2 no
Xq28 154044877 154079019 34.0 del - no
SCOS Xp22.33 2711073 2814530 103.5 del XG, GYG2 no
Xp22.2 16688233 16707403 19.2 dup SYAP1 no
Xp21.3 25568263 25583583 15.3 del - no
Xp11.3 44067590 44084085 16.5 dup EFHC2 no
Xq11.1 64806000 64854709 48.7 dup MSN no
Xq12 65385501 65413711 28.2 dup HEPH no
Xq22.3–q23 110226892 110965127 738.2 dup PAK3, CAPN6, DCX,
ALG13, TRPC5
no
Xq24 118780844 118798128 17.3 dup - no
Xq25 122920543 123009115 88.6 dup STAG2 no
Xq26.2 131413847 131439663 25.8 del MBNL3 no
Xq26.3 134600709 134628136 27.4 dup - yes
Yp11.2 7348864 7491480 142.6 dup - no
Y11.223 21964794 22058959 94.2 dup RBMY2EP (AZFb/bc) yes
Y11.23 26870161 27073218 203.1 dup - yes
SCOS=Sertoli-cell-only syndrome. Gene information - name, location, IDs - available as TableS1.
doi:10.1371/journal.pone.0019426.t005
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implied in spermatogenesis. When comparing results of these and
the current study, CNVs in the PLEC, TSPAN7, PAK3, TRCP5,
H2BFWT loci were found not only in men with SCOS, but also in
either patients with POF or XY gonadal dysgenesis (personal
communication). These cover 5 of 11 genes identified in the
current study which might hint to a common genetic origin of loss
of spermatogonia in the male and loss of oogonia in the female
resulting in SCOS, XY gonadal dysgenesis and POF, respectively.
With sperm counts ranging from zero to hundreds of millions
per ejaculate, sperm output may be viewed as a quantitative
trait and male infertility is sometimes postulated as a polygenic
disease [26]. Some evidence for this hypothesis may be gained
from the significant negative correlation between sperm counts
and number of deletions described in our 78 normozoospermic
men analysed by 244A array. Especially as hundreds of genes
are implicated in spermatogenesis, it is plausible that more
deletions also more often involve spermatogenesis-relevant
genes. Therefore, a man bearing more deletions may have a
less efficient spermatogenesis and therefore lower sperm output.
We could, however, not detect a comparable correlation in the,
albeit at most half as large, groups of normozoospermic men
analysed by 400K arrays or in oligozoospermic patients
(irrespective of array used).
While on the one hand the selection of our control group from
the patient clientele avoids population stratification, on the other
Table 6. Candidate genes with proposed function.
Group Phenotype Region Gene symbol OMIM Function
Risk factor Normo, Oligoz., SCOS 4q13.2 UGT2B17 601903 glucuronidase essential for urinary
testosterone excretion [23,24]
Recurring, patient-specific
CNVs
4xOligoz./3xSCOS 3p11.1 EPHA3 179611 Anks proteins involved in
modulating degradation of EphA
receptors [25]
2xOligoz. 6p21.31 ANKS1A 608994
2xSCOS 12q23.1 ANKS1B 607815
2xSCOS 8q24.3 PLEC 601282 Plectin in Sertoli cells concentrated
at intercellular junctions and nuclear
surface [29]
2xOligoz. 16q22.1 PRMT7 610087 protein methyltransferase,
cooperates with the testis-specific
factor CTCFL [30]
Private, sex-chromosomal,
patient-specific CNVs
1xOligoz. Xp11.4 TSPAN7 300096 interaction with SPAG11B (sperm
associated antigen) isoform D,
associated with spermatozoa [31]
1xOligoz. Xp11.22 SSX7 300542 cancer-testis antigen, expressed in
normal testis tissue [32,33]
1xOligoz. Xp11.22 SPANXN5 300668 cancer-testis antigen, expressed in
post-meiotic spermatids [34]
1xOligoz. Xq22.1 BEX1 300690 in mice: expression in pachytene
spermatocytes and spermatids [35]
1xOligoz. Xq22.1 NXF3 300316 belongs to a family of nuclear RNA
export factors (NXF), Nxf2 plays a
role in spermatogenesis (meiosis
and maintenance) [36,37]
1xOligoz. Xq22.2 H2BFWT 300507 testis-specific histone, SNP in 59
untranslated region associated with
oligozoospermia [38–40]
1xOligoz./1xSCOS Xq22.3 PAK3 300142 one isoform specifically expressed in
testis [41]
1xSCOS Xq23 TRPC5 300334 interacts and co-localises with
Enkurin in sperm [42]
OMIM=Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim); Oligoz.=Oligozoospermia; SCOS=Sertoli-cell-only syndrome. Gene
information - name, location, IDs - available as Table S1.
doi:10.1371/journal.pone.0019426.t006
Figure 5. Significant negative correlation (r=20.270, P,0.05)
of total sperm count with number of deletions in 78
normozoospermic men analysed by 244A array. P-value calcu-
lated on log-transformed total sperm counts.
doi:10.1371/journal.pone.0019426.g005
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phenotype of spermatogenic failure and cannot be readily
extended to fertility. For this purpose, a group of proven fertile
men (fathers) would be needed as additional controls. However,
at least one-fifth of our normozoospermic controls had fathered a
child before then presenting with either secondary infertility or
infertility in a new relationship. Contrariwise, the usually utilised
Database of Genomic Variants (DGV) of ‘healthy’ controls is not
amenable to be used with respect to the phenotype of
spermatogenic impairment, as the fertility status (let alone
spermatogenesis) is unknown. Thus, as a larger group of proven
fertile men was neither available to us nor has - to our knowledge
- been analysed anywhere else yet, our control group may well be
used to study spermatogenesis. The CNV data of the 100 controls
is provided as supplement as well as accessible through dbVar
and will be valuable for other studies on genetics of male
infertility.
In contrast to many candidate-gene approaches, only one
recently published study analysed 80 men with normozoosper-
mia, 52 with OAT, and 40 with non-obstructive azoospermia
(histology not mentioned) using whole genome SNP arrays [27].
Twenty-one SNPs were found significantly associated with azoo-
or oligozoospermia, but only four could be replicated in a larger
follow-up study [28]. We applied a more stringent patient
selection especially for the group of azoospermia as the known
histology of SCOS leads to one of the most homogeneous
phenotypes possible in male infertility. Accordingly, we could
identify a larger number of putative causal CNVs/genes in SCOS
than in oligozoospermia. All the recurring, patient-specific and
private, sex-chromosomal CNVs as well as the CNVs associated
with SCOS described herein are candidates deserving further
detailed analyses in larger patient and control groups as well as
other populations. Especially with respect to the sex-chromo-
somal CNVs, analyses of trios would be helpful to determine their
relevance. It should be considered, however, that involving the
parents of infertile patients is very difficult in comparison to other
diseases.
In conclusion, by the first CNV study in male infertility, we
provide evidence that CNVs contribute to the complex origin of
male infertility and present a number of candidate genes possibly
causing or being risk factors for spermatogenic failure.
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